Video
Survey Shows 65% of Affected Americans Want Access to Psychedelic Treatments for Mental Health Conditions
Data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded treatment offering that would include psychedelic medicines.
Pharmacy Times interviewed Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, on the implications of a survey that showed 65% of affected Americans want access to psychedelics for the treatment of mental health conditions.
Specifically, data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder (PTSD) are among those who would benefit from an expanded therapeutic regimen that includes psychedelic medicines, which have been found to be both effective and safe in the treatment of these conditions.
During the discussion, Marques explained how treatment-resistant depression, anxiety, and PTSD are currently defined, how psychedelic medicine works differently than other current treatments on the market for these conditions, and why there has been increased attention recently on psychedelic medicine for these conditions rather than further investigation into other less potentially controversial pharmaceutical treatments.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
